Nothing said here yet.
to join the conversation.
| Meeker David PPresident and CEO | Sell | 30,746 | $3.1M | Mon, Sep 14 |
| Meeker David PPresident and CEO | Sell | 8,698 | $899.6K | Mon, Sep 14 |
| Meeker David PPresident and CEO | Sell | 6,439 | $655.1K | Mon, Sep 14 |
| Meeker David PPresident and CEO | Sell | 2,300 | $241.9K | Mon, Sep 14 |
| Meeker David PPresident and CEO | Sell | 1,817 | $190.0K | Mon, Sep 14 |
| Smith Hunter CChief Financial Officer | Sell | 28,188 | $3.0M | Mon, Aug 31 |
| Smith Hunter CChief Financial Officer | Sell | 23,072 | $2.4M | Mon, Aug 31 |
| Smith Hunter CChief Financial Officer | Sell | 11,514 | $1.2M | Mon, Aug 31 |
| Shulman JosephChief Technical Officer | Sell | 5,079 | $608.2K | Thu, Aug 13 |
| Garfield AlastairChief Scientific Officer | Sell | 3,400 | $402.2K | Thu, Aug 13 |
| Garfield AlastairChief Scientific Officer | Sell | 2,007 | $233.0K | Thu, Aug 13 |
| Garfield AlastairChief Scientific Officer | Sell | 1,556 | $182.2K | Thu, Aug 13 |
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recent developments in the Prader-Willi syndrome treatment market, including progress on targeted therapies such as Rhythm Pharmaceuticals’ setmelanotide, have strengthened the company’s position in this rare disease space.
Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics.
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.